Use of biomarker in the preparation of kit used in method for early warning of prognosis risk in patient with acute st-segment elevation myocardial infarction

Abstract

Disclosed is a method for early warning of a prognosis risk in a patient with acute ST-segment elevation myocardial infarction. The biomarker comprises HBP. The present application can effectively evaluate whether patients with acute ST-segment elevation myocardial infarction will experience poor prognosis within 30 days after PCI by monitoring changes in HBP levels, thereby achieving early identification and timely clinical intervention for high-risk patients, improving the response speed and effect of treatment, reducing the incidence of adverse cardiovascular events, and ultimately improving prognosis of patients.

Dependencies are inferred from the claim text.